Wells Fargo & Company Puma Biotechnology, Inc. Transaction History
Wells Fargo & Company
- $507 Billion
- Q3 2025
A detailed history of Wells Fargo & Company transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 32,531 shares of PBYI stock, worth $161,028. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,531
Previous 28,026
16.07%
Holding current value
$161,028
Previous $96,000
72.92%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding PBYI
# of Institutions
135Shares Held
35.2MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...